2023-03-07 09:59:02 ET
- Cardiol Therapeutics ( NASDAQ: CRDL ) said its lead oral drug candidate, CardiolRx (cannabidiol), significantly prevented cardiac dysfunction and the development of fibrosis and cardiomyocyte hypertrophy in a pre-clinical model of heart failure and reduced expression of key inflammatory and fibrotic markers, results from one of its international collaborating research centers demonstrated.
- The company is also developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure.
- ( CRDL ) is up ~4% .
For further details see:
Cardiol Therapeutics lead drug cannabidiol prevents cardiac dysfunction in preclinical trial